Pancreatic Cancer Clinical Trials in Baltimore

Showing 161-180 of 203 trials

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

NCT00499486

RATIONALE: Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well sirolimus works in treating patients with advanced pancreatic cancer.

Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins47 participantsStarted Jan 2005

Baltimore, Maryland, United States

COMPLETEDPhase 2< 1 mile

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

NCT00003546

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine plus radiation therapy in treating patients with pancreatic cancer that cannot be removed surgically.

Pancreatic Cancer

Alliance for Clinical Trials in Oncology43 participantsStarted Sep 1998

Birmingham, Alabama, United States • La Jolla, California, United States • San Francisco, California, United States +45 more locations

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer

Pancreatic Cancer Trials in Other Cities

Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer

Gemcitabine Alone or in Combination With Other Chemotherapy Drugs in Treating Patients With Metastatic Cancer of the Pancreas

Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Immunotoxin Therapy in Treating Patients With Advanced Cancer

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Maintenance Dovitinib for Colorectal and Pancreas Cancer

Study of Pemetrexed for Second-Line Pancreas Cancer

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Other Conditions in Baltimore